Arthneeti
All Q2 FY27 results →
TP

Torrent Pharmaceuticals Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Torrent Pharmaceuticals Q2 Results 2026 (FY27) statement: Revenue & Margins

Q2 FY27 results statement: what the company reported on revenue, margins and order book.

Price₹4,524
Market cap₹1.7L Cr
P/E77.1
Updated24 Oct 2026
Read3 min read

Torrent Pharmaceuticals Ltd Q2 FY27 key numbers

Revenue
Q2 FY27 Revenue: Rs. 4,979 crores, up 51% YoY.

As stated in Torrent Pharmaceuticals Ltd's Q2 FY27 results statement · published 24 Oct 2026. Reported figures, not investment advice.

Based on Torrent Pharmaceuticals Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

The short version

Q2 FY27 Revenue: Rs. Q2 FY27 Financials (Quarter ended September 30, 2026): - EBITDA: Rs.

From Torrent Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 24 Oct 2026.

Revenue & Sales Performance

  • Q2 FY27 Revenue: Rs. 4,979 crores, up 51% YoY (Page 23).
  • Base Business Revenue (Q2 FY27): Rs. 3,893 crores, up 18% YoY (Page 24).
  • India Revenue (Q2 FY27): Rs. 2,181 crores, up 20% (India Rx business - Page 25).
  • Brazil Revenue (Q2 FY27): Rs. 440 crores, up 38% (Page 24).
  • US Revenue (Q2 FY27): Rs. 417 crores, up 24% (Page 24).
  • Germany Revenue (Q2 FY27): Rs. 283 crores, down 7% (Page 24).
  • International business (US + Emerging + CDMO): Rs. 406 crores, down 7% (Page 25).

2 more points from Torrent Pharmaceuticals Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

  • Q2 FY27 Financials (Quarter ended September 30, 2026):
  • EBITDA: Rs. 1,666 crores, up 54% YoY (Q2 FY26: Rs. 1,083 crores)
  • Operating Margin (Op. EBITDA margin): 33.5% (Q2 FY26: 32.8%)
  • Profit After Tax (PAT): Rs. 534 crores, down 9.6% YoY (Q2 FY26: Rs. 591 crores)
  • Operating Margin Calculation (Q2 FY27):
  • Operating Margin reported as 33.5% in the presentation (page 23), consistent with EBITDA margin figures.
  • Margin Outlook:

2 more points from Torrent Pharmaceuticals Ltd's call on margins

Pro opens every point from 15K+ earnings calls

Order Book & Pipeline

The investor presentation does not explicitly report on order book, order inflow, or pending orders. It primarily provides financial disclosures and ratios, audit reports, cash flow statements, balance sheets, and regulatory compliance information. Specific points: - The presentation includes detailed financial results (standalone and consolidated) for quarters and half-years ended September 30, 2026. - It contains additional disclosures as per SEBI regulations, including debt, equity, profitability ratios, and coverage ratios.

2 more points from Torrent Pharmaceuticals Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Torrent Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹5.0K Cr, net profit ₹534 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Torrent Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Sakar Healthcare Ltd (Q2 FY27)

    2,985.57 lakh (approximately 51.9% growth) . Key results statement takeaways from Sakar Healthcare Ltd's Q2 FY27 results statement — and how it ranks against se

  • Dr Reddys Laboratories Ltd (Q2 FY27)

    Reported Q2FY27 revenues: ₹8,671 Cr, up 1.5% YoY and 7% QoQ (Page 4). Key investor presentation takeaways from Dr Reddys Laboratories Ltd's Q2 FY27 investor pre

  • Beta Drugs Ltd (Q2 FY27)

    H1 FY25: ₹180 Crs . Key investor presentation takeaways from Beta Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

  • Bajaj Healthcare Ltd (Q2 FY27)

    Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Zydus Lifesci.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Torrent Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Torrent Pharmaceuticals Ltd Q2 FY27 results?

Q2 FY27 Revenue: Rs. Q2 FY27 Financials (Quarter ended September 30, 2026): - EBITDA: Rs.

What is Torrent Pharmaceuticals Ltd share price analysis?

Torrent Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 77.1 with a market cap of ₹172,082 Cr. Investors should review the full earnings analysis for detailed insights.

Is Torrent Pharmaceuticals Ltd planning capital expenditure?

The provided pages of the Torrent Pharmaceuticals results statement do not contain any specific information related to capex, capacity expansion, new plants, or projects including amounts, status, or timelines.

Keep Torrent Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.